Skip to main content
. 2023 Apr 18;7(18):5446–5457. doi: 10.1182/bloodadvances.2022009274

Table 2.

Transplant outcomes

30 days 100 days 1 y 4 y
HHV-6 reactivation (CI) 46% ± 7% 57% ± 7%
Clinically relevant HHV-6 infection (CI) 20% ± 5% 24% ± 6%
Grade 2, 3 or 4 aGVHD (CI) 28% ± 6%
Grade 3 or 4 aGVHD (CI) 13% ± 4%
cGVHD (CI) 25% ± 6% 33% ± 6%
TRM (CI) 18 % ± 5% 26% ± 6%
Relapse (CI) 26% ± 6% 32% ± 6%
OS 64% ± 6% 47% ± 7%
PFS 56% ± 7% 42% ± 7%

aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.